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background: Metformin is the first line drug for patients with type-2 diabetes. The impact of different treatment escalation strategies after 
metformin failure on glucose control and morbidity has however not been investigated in real life.
methods: DiaRegis is a multicenter registry in 3,810 patients with type-2 diabetes. For the present analysis we selected patients with metformin 
monotherapy at baseline, and the addition of either incretin-based drugs (Metformin/Incretin), Sulfonylureas (Metformin/Sulfonylurea), or Insulin.
results: At baseline 2,064 patients received metformin monotherapy. An incretin-based treatment strategy (DPP-4 I or GLP-1 A) was added in 
38.0% of patients (n=783), sulfonylurea in 15.7% (n=324) and an insulin based treatment strategy chosen in 12.9% (n=266). For 81.7% of these a 
2 year FU was available of which 65.4% retained the originally chosen treatment strategy (metformin/incretin n=421; metformin/SU n=154; insulin 
n=151). Compared to metformin/incretin, metformin/SU resulted in a higher HbA1c reduction vs. baseline (-0.6 ±1.4% vs. -0.5±1.0%; p=0.039). 
Insulin resulted in a stronger reduction of HbA1c (-0.9±2.0% vs. -0.5±1.0%; p=0.003), and fasting plasma glucose (-24±70 mg/dl vs. -19±42 mg/
dl; p=0.001) but was associated with an elevated bodyweight (0.8±9.0 kg vs. -1.5±5.0 kg; p=0.028) after 2 year follow-up compared to metformin/
incretin. Hypoglycaemia rates where increased for patients receiving insulin (OR 8.35; 95%CI 4.84-14.4) and metformin/SU (OR 2.70; 95%CI 1.48-
4.92) compared to metformin/incretin. While there was no difference in event rates between metformin/incretin and metformin/SU, insulin was 
associated with higher rates of death (OR 4.65; 95%CI 1.68-12.9), major cardiac and cerebrovascular events (OR 3.08; 95%CI 1.27-7.48) and 
incident microvascular disease (OR 3.84; 95%CI 2.13-6.90).
conclusions: Taking the results of DiaRegis into consideration it can be concluded that increatin-based treatment strategies are preferable over 
sulfonylureas or insulin in subjects failing on metformin monotherapy in patients with type 2 diabetes. This has been reflected in recent guidance on 
the treatment of type-2 diabetes.
